Mode
Text Size
Log in / Sign up
Phase 2 Completed N=350 Randomized Quadruple-blind Treatment

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Source: ClinicalTrials.gov NCT01735630 ↗
Enrolled (actual)
350
Serious AEs
6.3%
Results posted
Aug 2016
Primary outcomePrimary: Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A). — -4.3; -4.2 units on a scale

Summary

The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).
-4.3; -4.2
SECONDARY
Change From Baseline in Modified-ADCS-CGIC Agitation Scores
3.6; 3.4
SECONDARY
Change From Baseline in NPI Total Scores
-14.38; -15.12
SECONDARY
Change From Baseline in MMSE Scores
-0.3; -0.4
SECONDARY
Change From Baseline in ADCS-ADL Scores
-1.458; -2.229

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Probable AD according to the National Institute on Aging- Alzheimer's Association (NIA-AA) guidelines (McKhann et al 2011).
  • MMSE score of 5 to 24 (inclusive) at the Screening Visit.
  • Has clinically significant agitation/aggression defined as Neuropsychiatric Inventory (NPI)-agitation/aggression subscore of ≥4.
  • No response or suboptimal response to standard nonpharmacological interventions.

Exclusion Criteria

  • The agitation/aggression is attributable to concomitant medications, environmental conditions, or active medical or psychiatric condition.
  • Current diagnosis of major depressive disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM IV TR).
  • Has persistent and distressing psychotic symptoms (delusion and/or hallucinations) that require psychiatric hospitalization.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01735630). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search